CELL INTELLIGENCE · 肿瘤细胞治疗研究

寻找 AML 中安全有效的 CAR-T 靶点

The search for safe and effective CAR-T targets in AML.

CAR-T 细胞治疗临床试验全景与发展趋势的全球多维分析

A global multidimensional analysis of the chimeric antigen receptor T-cell therapy clinical trial landscape and development trends.

用 TCR 模拟抗体工程化 T 细胞进行三特异性靶向以限制抗原逃逸

Trispecific targeting of T cells engineered with TCR mimic antibodies to limit antigen escape.

靶向 WT1 肽/HLA-A2 复合物的免疫蛋白酶体依赖性和非依赖性表位的三特异性 T 细胞，加上识别第三种肿瘤相关抗原的 CSR，提供了一种有效且经济高效的方法来克服肿瘤免疫逃逸。

CD33(KO)-CD33-mesothelin Loop CAR 设计避免自相残杀并提高 iNK 细胞抗急性髓系白血病的疗效

CD33(KO)-CD33-mesothelin Loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemia.

Loop CAR 赋予 UCB-NK 细胞和 hPSC-iNK 细胞更强的针对 CD33 + MSLN + 肿瘤细胞的细胞毒性。

NKG2D/CD28 嵌合受体增强针对实体瘤和血液肿瘤的 CAR-T 细胞细胞毒性与持久性

NKG2D/CD28 chimeric receptor boosts cytotoxicity and durability of CAR-T cells for solid and hematological tumors.

CAR 与 NKG2D/CD28 的联合提供了一种增强 CAR-T 细胞细胞毒性和持久性的有效策略。

源自诱导多能干细胞的间皮素靶向 CAR-NK 细胞在多种临床前模型中高效杀伤三阴性乳腺癌细胞

Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Sh

多链 DAP-CAR 工程化 T 细胞中 c-Jun 共表达用于实体瘤治疗

Coexpression of c-Jun in multiple-chain DAP-CAR-engineered T-cells for solid tumor therapy.

显性负性转化生长因子-β 受体装甲的间皮素靶向 CAR-T 细胞在卵巢癌小鼠模型中减缓肿瘤生长

Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse m

靶向间皮素的免疫治疗在急性髓系白血病中的应用

Immunotherapy targeting mesothelin in acute myeloid leukemia.

间皮素：超越实体瘤的免疫治疗靶点

Mesothelin: An Immunotherapeutic Target beyond Solid Tumors.